Orthocell logo

OCC - Orthocell Share Price

A$0.32 0.0  6.7%

Last Trade - 2:37am

Sector
Healthcare
Size
Micro Cap
Market Cap £27.1m
Enterprise Value £16.9m
Revenue £416k
Position in Universe 742nd / 1836
Bullish
Bearish
Unlock OCC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OCC Revenue Unlock OCC Revenue

Net Income

OCC Net Income Unlock OCC Revenue

Normalised EPS

OCC Normalised EPS Unlock OCC Revenue

PE Ratio Range

OCC PE Ratio Range Unlock OCC Revenue

Dividend Yield Range

OCC Dividend Yield Range Unlock OCC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OCC EPS Forecasts Unlock OCC Revenue
Profile Summary

Orthocell Limited is a regenerative medicine company. The Company is engaged in the development and commercialization of cell therapies and related technologies. The Company's products include CelGro, a collagen medical device for soft tissue repair in use as an augment to rotator cuff repair, guided bone regeneration and repair of articular cartilage, and Autologous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon regeneration. CelGro is targeted on a range of orthopedic, reconstructive and surgical applications. Ortho-ATI is a treatment that uses a minimally invasive, non-surgical approach that uses each patient's own tendon derived stem cells to stimulate tendon regeneration and is delivered through ultrasound guided injection under local anesthetic. The Company's Autologous Chondrocyte Implantation (Ortho-ACI) offers treatment for symptomatic defects of the articulating cartilage of the joints, including the knee and ankle.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated March 21, 2006
Public Since August 12, 2014
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 184,354,764
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OCC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OCC
Upcoming Events for OCC
Similar to OCC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.